Mutations in the C-terminus of CDKL5: proceed with caution.

Eur J Hum Genet

1] Laboratoire de Biochimie et Génétique Moléculaire, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France [2] Inserm, U1016, Paris, France [3] Institut Cochin, Université Paris Descartes, Sorbonne Paris Cité, CNRS (UMR 8104), Paris, France.

Published: February 2014


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene have been described in girls with Rett-like features and early-onset epileptic encephalopathy including infantile spasms. Milder phenotypes have been associated with sequence variations in the 3'-end of the CDKL5 gene. Identification of novel CDKL5 transcripts coding isoforms characterized by an altered C-terminal region strongly questions the eventual pathogenicity of sequence variations located in the 3'-end of the gene. We investigated a group of 30 female patients with a clinically heterogeneous phenotype ranging from nonspecific intellectual disability to a severe neonatal encephalopathy and identified two heterozygous CDKL5 missense mutations, the previously reported p.Val999Met and the novel mutation p.Pro944Thr. However, these mutations have also been detected in their healthy father. Considering our results and all data from the literature, we suggest that genetic variations beyond the codon 938 in human CDKL5115 protein may have minor or no significance. It is probable that screening of exons 19-21 of the CDKL5 gene is not useful in practical molecular diagnosis of atypical Rett syndrome.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895649PMC
http://dx.doi.org/10.1038/ejhg.2013.133DOI Listing

Publication Analysis

Top Keywords

cdkl5 gene
12
sequence variations
8
cdkl5
6
mutations
4
mutations c-terminus
4
c-terminus cdkl5
4
cdkl5 proceed
4
proceed caution
4
caution mutations
4
mutations cyclin-dependent
4

Similar Publications

CDKL5 Deficiency Disorder (CDD) is a severe neurodevelopmental disorder caused by mutations in the X-linked CDKL5 gene, resulting in early-onset seizures, developmental delays, and cognitive and sensorimotor impairments. While emerging therapies show promise, substantial challenges remain in developing a cure for CDD. In our prior work, we developed an innovative gene therapy strategy based on an Igk-TATk-CDKL5 fusion protein, which enhances brain distribution of the therapeutic protein, significantly improving treatment efficacy in a Cdkl5 knockout male mouse model.

View Article and Find Full Text PDF

CDKL5 deficiency disorder is a rare and severe developmental and epileptic encephalopathy that has profound effects on communication. It is essential that communication be measured accurately for upcoming gene therapy trials. The Communication Inventory Disability-Observer Reported (CID-OR) was developed from a framework of communication derived from parent/caregiver interview data (n = 23), in consultation with disability and communication experts, and after reviewing concepts in existing measures.

View Article and Find Full Text PDF

Symptom Onset in Classic Rett Syndrome: Analysis of Initial Clinical Severity Scale Entries.

Ann Child Neurol Soc

June 2025

University of Pennsylvania, Perelman School of Medicine, Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA.

Objective: To assess clinical features of Rett Syndrome (RTT) at registration into the NIH-sponsored Natural History (NH) study using the Clinical Severity Scale (CSS).

Introduction: The CSS was established in 2000 to assess characteristics of individuals with RTT and related disorders. We analyzed the CSS at enrollment into the NH study of all individuals with classic RTT.

View Article and Find Full Text PDF

Neurogenetic biomarkers in epilepsy: A comprehensive narrative review of progression and therapeutic approaches.

Mutat Res Rev Mutat Res

August 2025

Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab 142001, India. Electronic address:

Epilepsy is a multifaceted and heterogenous neurological disorder that affects an estimated 70 million people worldwide and is identified by recurrent or unprovoked seizure activity. Although there have been advances in pharmacotherapeutic treatments, approximately one-third of patients with epilepsy remain drug resistant, highlighting the need for personalised and mechanism-based strategies. Neurogenetic biomarkers are emerging as valuable instruments for translating the genetic findings to the bedside and may provide new opportunities within a more precise treatment paradigm in epilepsy.

View Article and Find Full Text PDF

Introduction: Developmental and epileptic encephalopathy (DEE) is epilepsy related to developmental impairment that may be caused by both the underlying etiology (developmental encephalopathy) and superimposed epileptic activity (epileptic encephalopathy). The origin of DEE and the causes of its variations remain unknown. Owing the lack of clarity regarding the role of genetic variables in DEE, we conducted a scoping review to qualitatively identify the genes most important in the development of DEE to provide an up-to-date review.

View Article and Find Full Text PDF